WHO, Depression and other common mental disorders: Global Health Estimates. 2017.
Pandarakalam JP. Challenges of treatment-resistant depression. Psychiatr Danub. 2018;30(3):273–84.
Delgado PL. Depression: the case for a monoamine deficiency. J Clin Psychiatry. 2000;61(Suppl 6):7–11.
Price JB, et al. Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression. Neurosci Biobehav Rev. 2018;90:212–20.
Andrade C, Arumugham SS, Thirthalli J. Adverse effects of electroconvulsive therapy. Psychiatr Clin North Am. 2016;39(3):513–30.
Kayser S, et al. Antidepressant effects, of magnetic seizure therapy and electroconvulsive therapy, in treatment-resistant depression. J Psychiatr Res. 2011;45(5):569–76.
Fitzgerald PB, et al. Pilot study of the clinical and cognitive effects of high-frequency magnetic seizure therapy in major depressive disorder. Depress Anxiety. 2013;30(2):129–36.
• Wang J, et al. Accelerated magnetic seizure therapy for treatment of major depressive disorder: a report of 3 cases. J ECT. 2019;35(2):135–8 Open-label trial that shows that MST provokes no side effects and improved immediate and delayed verbal memory indices.
• Fitzgerald PB, et al. A pilot study of the comparative efficacy of 100 Hz magnetic seizure therapy and electroconvulsive therapy in persistent depression. Depress Anxiety. 2018;35(5):393–401 Randomized double-blind trial comparing ECT and MST.
Kayser S, et al. Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects. Psychol Med. 2015;45(5):1073–92.
•• Sun Y, et al. Magnetic seizure therapy reduces suicidal ideation and produces neuroplasticity in treatment-resistant depression. Transl Psychiatry. 2018;8(1):253 Provides evidence of MST inducing neuroplasticity.
Conway CR, et al. Association of cerebral metabolic activity changes with vagus nerve stimulation antidepressant response in treatment-resistant depression. Brain Stimul. 2013;6(5):788–97.
Perini GI, et al. Hippocampal gray volumes increase in treatment-resistant depression responding to vagus nerve stimulation. J ECT. 2017;33(3):160–6.
Gorgulho AA, et al. Double blinded randomized trial of subcutaneous trigeminal nerve stimulation as adjuvant treatment for major unipolar depressive disorder. Neurosurgery. 2019;85(5):717–28.
Cook IA, et al. Trigeminal nerve stimulation in major depressive disorder: acute outcomes in an open pilot study. Epilepsy Behav. 2013;28(2):221–6.
Shiozawa P, et al. Effect of a 10-day trigeminal nerve stimulation (TNS) protocol for treating major depressive disorder: a phase II, sham-controlled, randomized clinical trial. Epilepsy Behav. 2015;44:23–6.
•• Generoso MB, et al. Effect of a 10-day transcutaneous trigeminal nerve stimulation (TNS) protocol for depression amelioration: a randomized, double blind, and sham-controlled phase II clinical trial. Epilepsy Behav. 2019;95:39–42 Most recent double-blind, sham-controlled trials of sTNS.
Silverman DGC, Cook I, DeGiorgio C, Miller P, Susselman M, Schrader L. Effects of trigeminal nerve stimulation on regional brain activity in depression. J Nucl Med. 2011;52.
Tye SJ, Frye MA, Lee KH. Disrupting disordered neurocircuitry: treating refractory psychiatric illness with neuromodulation. Mayo Clin Proc. 2009;84(6):522–32.
Dougherty DD, et al. A randomized sham-controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biol Psychiatry. 2015;78(4):240–8.
Holtzheimer PE, et al. Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. Lancet Psychiatry. 2017;4(11):839–49.
Mayberg HS, et al. Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45(5):651–60.
Bergfeld IO, et al. Deep brain stimulation of the ventral anterior limb of the internal capsule for treatment-resistant depression: a randomized clinical trial. JAMA Psychiatry. 2016;73(5):456–64.
Bewernick BH, et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. 2010;67(2):110–6.
Sartorius A, et al. Remission of major depression under deep brain stimulation of the lateral habenula in a therapy-refractory patient. Biol Psychiatry. 2010;67(2):e9–e11.
Malone DA Jr, et al. Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009;65(4):267–75.
Fenoy AJ, et al. A longitudinal study on deep brain stimulation of the medial forebrain bundle for treatment-resistant depression. Transl Psychiatry. 2018;8(1):111.
Schlaepfer TE, et al. Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology. 2008;33(2):368–77.
Millet B, et al. Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: accumbens more promising than caudate. Eur Neuropsychopharmacol. 2014;24(8):1229–39.
• Brown EC, et al. Metabolic activity in subcallosal cingulate predicts response to deep brain stimulation for depression. Neuropsychopharmacology. 2020;45(10):1681–8 Recent study providing evidence of modulation of metabolic activity through DBS to SCC.
Hoyer C, et al. Long-term course of brain-derived neurotrophic factor serum levels in a patient treated with deep brain stimulation of the lateral habenula. Neuropsychobiology. 2012;65(3):147–52.
Riva-Posse P, et al. Defining critical white matter pathways mediating successful subcallosal cingulate deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2014;76(12):963–9.
• Liebrand LC, et al. Distance to white matter trajectories is associated with treatment response to internal capsule deep brain stimulation in treatment-refractory depression. Neuroimage Clin. 2020;28:102363 Provides evidence of enhanced treatment response through white matter stimulation.
Coenen VA, et al. Tractography-assisted deep brain stimulation of the superolateral branch of the medial forebrain bundle (slMFB DBS) in major depression. Neuroimage Clin. 2018;20:580–93.
•• Riva-Posse P, et al. A connectomic approach for subcallosal cingulate deep brain stimulation surgery: prospective targeting in treatment-resistant depression. Mol Psychiatry. 2018;23(4):843–9 Demonstrates that treatment response could be enhanced when stimulating a connectome of four white matter bundles.
Fitzgerald PB, et al. A pilot investigation of an intensive theta burst stimulation protocol for patients with treatment resistant depression. Brain Stimul. 2020;13(1):137–44.
•• Blumberger DM, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet. 2018;391(10131):1683–92 The first randomized non-inferiority trial to compare intermittent TBS treatment with rTMS.
Zavorotnyy M, et al. Intermittent theta-burst stimulation moderates interaction between increment of N-acetyl-aspartate in anterior cingulate and improvement of unipolar depression. Brain Stimul. 2020;13(4):943–52.
Baeken C, Wu G, Sackeim HA. Accelerated iTBS treatment applied to the left DLPFC in depressed patients results in a rapid volume increase in the left hippocampal dentate gyrus, not driven by brain perfusion. Brain Stimul. 2020;13(5):1211–7.
Padberg F, et al. Prefrontal transcranial direct current stimulation (tDCS) as treatment for major depression: study design and methodology of a multicenter triple blind randomized placebo controlled trial (DepressionDC). Eur Arch Psychiatry Clin Neurosci. 2017;267(8):751–66.
Brunoni AR, et al. The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial. JAMA Psychiatry. 2013;70(4):383–91.
Player MJ, et al. Increase in PAS-induced neuroplasticity after a treatment course of transcranial direct current stimulation for depression. J Affect Disord. 2014;167:140–7.
Rohan M, et al. Low-field magnetic stimulation in bipolar depression using an MRI-based stimulator. Am J Psychiatry. 2004;161(1):93–8.
• Dubin MJ, et al. A double-blind pilot dosing study of low field magnetic stimulation (LFMS) for treatment-resistant depression (TRD). J Affect Disord. 2019;249:286–93 Recent double-blind randomized controlled trial of LFMS in TRD.
Rohan ML, et al. Rapid mood-elevating effects of low field magnetic stimulation in depression. Biol Psychiatry. 2014;76(3):186–93.
•• Xiao L, et al. Rhythmic low-field magnetic stimulation may improve depression by increasing brain-derived neurotrophic factor. CNS Spectr. 2019;24(3):313–21 Suggests that LFMS antidepressant efficacy might be related to modulation of BDNF.
Sakaguchi Y, et al. Apoptosis in tumors and normal tissues induced by whole body hyperthermia in rats. Cancer Res. 1995;55(22):5459–64.
Janssen CW, et al. Whole-body hyperthermia for the treatment of major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2016;73(8):789–95.
Hanusch KU, et al. Whole-body hyperthermia for the treatment of major depression: associations with thermoregulatory cooling. Am J Psychiatry. 2013;170(7):802–4.
Szmulewicz AG, et al. Dopaminergic agents in the treatment of bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand. 2017;135(6):527–38.
Wolke SA, et al. Modulation of anterior cingulate cortex reward and penalty signalling in medication-naive young-adult subjects with depressive symptoms following acute dose lurasidone. Psychol Med. 2019;49(8):1365–77.
• Raison CL, et al. C-reactive protein and response to lurasidone in patients with bipolar depression. Brain Behav Immun. 2018;73:717–24 Shows that antidepressant response to lurasidone is enhanced with increasing levels of pre-treatment C-reactive protein.
Eaves S, Rey JA. Brexpiprazole (Rexulti): a new monotherapy for schizophrenia and adjunctive therapy for major depressive disorder. P T. 2016;41(7):418–22.
Ma M, et al. Antidepressant effects of combination of brexpiprazole and fluoxetine on depression-like behavior and dendritic changes in mice after inflammation. Psychopharmacology. 2017;234(4):525–33.
Thase ME, et al. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76(9):1232–40.
De Carlo V, et al. Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: a naturalistic study. Hum Psychopharmacol. 2020;35(5):e2750.
Christensen MC, Loft H, McIntyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: a novel dual outcome measure in depressive disorders. J Affect Disord. 2018;227:787–94.
Fourrier C, et al. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo. Trials. 2018;19(1):447.
• Talmon M, et al. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol. 2018;175(1):113–24 Evidence of anti-inflammatory of vortioxetine effects in humans.
Eyre H, et al. Comparing the immune-genomic effects of vilazodone and paroxetine in late-life depression: a pilot study. Pharmacopsychiatry. 2017;50(6):256–63.
• Kornstein S, et al. Vilazodone efficacy in subgroups of patients with major depressive disorder: a post-hoc analysis of four randomized, double-blind, placebo-controlled trials. Int Clin Psychopharmacol. 2018;33(4):217–23 Evidence that vilazodone significantly reduces depressive symptoms in diverse subgroups of patients.
de Bodinat C, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628–42.
Englisch S, et al. Agomelatine for the treatment of major depressive episodes in schizophrenia-spectrum disorders: an open-prospective proof-of-concept study. J Clin Psychopharmacol. 2016;36(6):597–607.
De Berardis D, et al. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in “real-world,” everyday clinical practice. CNS Spectr. 2017;22(4):342–7.
Di Giannantonio M, et al. Major depressive disorder, anhedonia and agomelatine: an open-label study. J Biol Regul Homeost Agents. 2011;25(1):109–14.
Fuxe K, Borroto-Escuela DO. Basimglurant for treatment of major depressive disorder: a novel negative allosteric modulator of metabotropic glutamate receptor 5. Expert Opin Investig Drugs. 2015;24(9):1247–60.
Peterlik D, et al. Blocking metabotropic glutamate receptor subtype 5 relieves maladaptive chronic stress consequences. Brain Behav Immun. 2017;59:79–92.
Quiroz JA, et al. Efficacy and safety of basimglurant as adjunctive therapy for major depression: a randomized clinical trial. JAMA Psychiatry. 2016;73(7):675–84.
Karp JF, et al. Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults. J Clin Psychiatry. 2014;75(8):e785–93.
Serafini G, et al. The efficacy of buprenorphine in major depression, treatment-resistant depression and suicidal behavior: a systematic review. Int J Mol Sci. 2018:19(8).
Dilsaver SC. The pathophysiologies of substance abuse and affective disorders: an integrative model? J Clin Psychopharmacol. 1987;7(1):1–10.
Volker D, et al. Oral buprenorphine is anti-inflammatory and modulates the pathogenesis of streptococcal cell wall polymer-induced arthritis in the Lew/SSN rat. Lab Anim. 2000;34(4):423–9.
Hemshekhar M, et al. Buprenorphine alters inflammatory and oxidative stress molecular markers in arthritis. Mediat Inflamm. 2017;2017:2515408.
Murrough JW, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–6.
Correia-Melo FS, et al. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: a randomized, double-blind, non-inferiority study. J Affect Disord. 2020;264:527–34.
Singh JB, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–26.
•• Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry. 2019;176(6):428–38 A phase 3 randomized double-blind study on the recently approved esketamine nasal spray.
Zanos P, Gould TD. Mechanisms of ketamine action as an antidepressant. Mol Psychiatry. 2018;23(4):801–11.
Loix S, De Kock M, Henin P. The anti-inflammatory effects of ketamine: state of the art. Acta Anaesthesiol Belg. 2011;62(1):47–58.
•• El-Haggar SM, et al. The phosphodiesterase inhibitor pentoxifylline as a novel adjunct to antidepressants in major depressive disorder patients: a proof-of-concept, randomized, double-blind, placebo-controlled trial. Psychother Psychosom. 2018;87(6):331–9 The first randomized, double-blind, and placebo-controlled trial to explore pentoxifylline as an adjunctive therapy.
Siegel AN, et al. Novel therapeutic targets in mood disorders: Pentoxifylline (PTX) as a candidate treatment. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;104:110032.
•• Saccarello A, et al. Oral administration of S-adenosylmethionine (SAMe) and Lactobacillus plantarum HEAL9 improves the mild-to-moderate symptoms of depression: a randomized, double-blind, placebo-controlled study. Prim Care Companion CNS Disord. 2020;22(4) Demonstrates that the combination of SAMe and L. plantarum provides fast and significant improvement of mild and moderate depressive symptoms.
Cuomo A, et al. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. Ann General Psychiatry. 2020;19:50.
Sarris J, et al. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord. 2014;164:76–81.
Rudzki L, et al. Probiotic Lactobacillus plantarum 299v decreases kynurenine concentration and improves cognitive functions in patients with major depression: a double-blind, randomized, placebo controlled study. Psychoneuroendocrinology. 2019;100:213–22.
Andersson H, et al. Oral administration of Lactobacillus plantarum 299v reduces cortisol levels in human saliva during examination induced stress: a randomized, double-blind controlled trial. Int J Microbiol. 2016;2016:8469018.
•• Kamiya M, et al. Efficacy and safety of TS-121, a novel vasopressin V1B receptor antagonist, as adjunctive treatment for patients with major depressive disorder: a randomized, double-blind, placebo-controlled study. J Psychiatr Res. 2020;128:43–51 The first study to assess antidepressant efficacy of the V1B receptor antagonist TS-121 in TRD.
Agorastos A, et al. Vasopressin surrogate marker copeptin as a potential novel endocrine biomarker for antidepressant treatment response in major depression: a pilot study. Front Psychiatry. 2020;11:453.
Osher Y, Belmaker RH. Omega-3 fatty acids in depression: a review of three studies. CNS Neurosci Ther. 2009;15(2):128–33.
Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry. 2002;159(3):477–9.
Nemets H, et al. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry. 2006;163(6):1098–100.
Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry. 2005;66(6):726–9.
•• Yang B, et al. Clinical efficacy and biological regulations of omega-3 PUFA-derived endocannabinoids in major depressive disorder. Psychother Psychosom. 2019;88(4):215–24 The first double-blind, nonplacebo, randomized controlled trial on the effects of omega-3 PUFAs on EC levels and its association to PUFAs antidepressant efficacy.
Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res. 2014;52:1–6.
Larsen RJ, Kasimatis M, Frey K. Facilitating the furrowed brow: an unobtrusive test of the facial feedback hypothesis applied to unpleasant affect. Cognit Emot. 1992;6(5):321–38.
Magid M, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(8):837–44.
Leira Y, et al. Mild systemic inflammation enhances response to onabotulinumtoxinA in chronic migraineurs. Sci Rep. 2021;11(1):1092.